CHI Logo

 

Overview
Table of Contents
Order
Additional Reports 

Brochure Cover
Download Brochure 

Publication Date: 
February 2012

Page Count: 594

Price:
$2,695 Single User
$4,095 Multiple User
$8,095 Single Site
$13,475 Global License

Biomarker Partnering Terms and Agreements, 3rd Edition - Overview

 

Summary 

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Revised and updated 3rd edition, includes:

  • Trends in biomarker partnering deals
  • Deal terms analaysis
  • Average biomarker deal values
  • Biomarker partnering agreement structure
  • Biomarker partnering contract documents
  • Top biomarker deals by value
  • Most active biomarker dealmakers

 

> Download Brochure 

Description 

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 550 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in biomarker partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Key benefits 

Biomarker Partnering Terms and Agreements provides the reader with the following key benefits:

  • Trends in biomarker partnering deals
  • Deal terms analaysis
  • Average biomarker deal values
  • Biomarker partnering agreement structure
  • Biomarker partnering contract documents
  • Top biomarker deals by value
  • Most active biomarker dealmakers

Report scope 

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

  • Trends in biomarker dealmaking in the biopharma industry since 2007
  • Analysis of biomarker deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life biomarker deals
  • Access to over 550 biomarker contract documents
  • The leading biomarker deals by value since 2007
  • Most active biomarker dealmakers since 2007
  • The leading biomarker partnering resources

 

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand

By Series:
By Region: